Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer

Alflutinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations. Previous study has shown that after multiple dosages, alflutinib exhibits nonlinear pharmacokinetics and displays a time- and dose-dependent i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao-yun, Guo, Zi-tao, Chen, Zhen-dong, Zhang, Yi-fan, Zhou, Jia-lan, Jiang, Yong, Zhao, Qian-yu, Diao, Xing-xing, Zhong, Da-fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608132/
https://www.ncbi.nlm.nih.gov/pubmed/32235864
http://dx.doi.org/10.1038/s41401-020-0389-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608132/
https://www.ncbi.nlm.nih.gov/pubmed/32235864
http://dx.doi.org/10.1038/s41401-020-0389-3

Ejemplares similares